News
Researchers find a biomarker that predicts a good response to a new drug against breast cancer
Epigenetic inactivation of BRCA1 enhances the effect of PARP inhibitors in breast tumors Paper reference:
Manel Esteller, awarded by the International Union of Toxicology
IDIBELL’s researcher has been bestowed with the Deichmann Award
El Programa de teràpia cel·lular aproparà a la pràctica clínica els resultats de la recerca
The program’s objective is coordinating the efforts of twenty-four leading research groups working in the field of the stem cell translational research. Today, nineteen of these teams are clinical research groups (eighteen of them belong to IDIBAPS – Hospital Clinic de Barcelona and one to Bellvitge Biomedical Research Institute (IDIBELL). The five remaining centers provide […]
1.2 million euros for research on hereditary cancer
The project also involved ICO’s Cancer Prevention Program, the Medical Oncology Service at ICO L’Hospitalet de Llobregat, Bellvitge University Hospital and the Institute of Predictive and Personalized Medicine of Cancer (IMPPC). Candidates for AECC’s call are stable research groups that promote cancer research applied to clinical practice. The amount will be allocated over five years. […]
Caja Rural de Granada rewards Manel Esteller
The jury of the sixth edition of the Health Sciences Award from Caja Rural de Granada Foundation has been awarded the work presented by Manel Esteller, director of IDIBELL’s Epigenetics and Cancer Biology Program. This prize is worth 20,000 euros. The winning work has uncovered a connection between overgrowth and cancer. The award was presented […]